PMID- 26557908
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151111
LR  - 20181113
IS  - 1759-7706 (Print)
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Linking)
VI  - 6
IP  - 6
DP  - 2015 Nov
TI  - Efficacy of bronchoscopic biopsy for the detection of epidermal growth factor 
      receptor mutations and anaplastic lymphoma kinase gene rearrangement in lung 
      adenocarcinoma.
PG  - 709-14
LID - 10.1111/1759-7714.12245 [doi]
AB  - BACKGROUND: To explore the efficacy of bronchoscopic biopsy for the detection of 
      epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase 
      (ALK) gene rearrangement in lung adenocarcinoma. METHODS: All patients with 
      bronchoscopic biopsy-proven lung adenocarcinoma at the Peking Union Medical 
      College Hospital from January 2009 to November 2011 were enrolled. Scorpion 
      amplification refractory mutation system (ARMS) was used to detect EGFR gene 
      mutations and fluorescence in situ hybridization (FISH) to detect ALK 
      rearrangement. The correlation of immunohistochemistry (IHC) results with 
      standard methods for EGFR mutation status and ALK rearrangement were checked. 
      RESULTS: Bronchoscopic specimens were successfully used to detect EGFR mutation 
      and ALK rearrangement with success rates of 85.2% and 71.3%, respectively, in 
      non-small cell lung cancer patients. EGFR analysis by ARMS yielded a positive 
      result in 35.8% (33/92) and positive ALK rearrangement was detected by FISH in 
      7.8% (6/77) of cases. It was more likely to be unsuccessful in patients with 
      tumor cells less than 100/high power field and the ratio tumor numbers in 0-10%. 
      In EGFR-IHC, the sensitivity and specificity of E746-A750 deletions were 73.3% 
      (11/15) and 93.3% (70/75), respectively, and those of L858R were 93.3% (14/15) 
      and 93.2% (69/74), respectively. In ALK-IHC, the sensitivity and specificity were 
      50% (3/6) and 100% (71/71), respectively. CONCLUSIONS: Small bronchoscopic 
      specimens could achieve higher successful detection rates via EGFR mutation and 
      ALK gene rearrangement.
FAU - Zhu, Pei
AU  - Zhu P
AD  - Respiratory Department of Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Peking, China.
FAU - Pan, Qingqing
AU  - Pan Q
AD  - Respiratory Department of Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Peking, China.
FAU - Wang, Mengzhao
AU  - Wang M
AD  - Respiratory Department of Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Peking, China.
FAU - Zhong, Wei
AU  - Zhong W
AD  - Respiratory Department of Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Peking, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Respiratory Department of Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College Peking, China.
LA  - eng
PT  - Journal Article
DEP - 20150306
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
PMC - PMC4632922
OTO - NOTNLM
OT  - Biomarkers
OT  - bronchoscopy
OT  - immunohistochemistry
OT  - non-small cell lung cancer
EDAT- 2015/11/12 06:00
MHDA- 2015/11/12 06:01
PMCR- 2015/11/01
CRDT- 2015/11/12 06:00
PHST- 2014/12/18 00:00 [received]
PHST- 2015/01/12 00:00 [accepted]
PHST- 2015/11/12 06:00 [entrez]
PHST- 2015/11/12 06:00 [pubmed]
PHST- 2015/11/12 06:01 [medline]
PHST- 2015/11/01 00:00 [pmc-release]
AID - 10.1111/1759-7714.12245 [doi]
PST - ppublish
SO  - Thorac Cancer. 2015 Nov;6(6):709-14. doi: 10.1111/1759-7714.12245. Epub 2015 Mar 
      6.